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Radiochemical and biological evaluation
of novel 153Sm/166Ho-amino acid–chitosan
complexes
F. Marques,a L. Gano,a M. K. S. Batista,b,c C. A. R. Gomes,c P. Gomes,b
and I. Santosa
153Sm/166Ho-chitosan complexes have been considered promising agents for internal radiation therapy. By direct
administration, complexes solution converts into a gel, at physiological pH, allowing its retention for a long time. Herein,
we report on the synthesis of 153Sm/166Ho complexes with the novel amino acid–chitosan polymers, N-(c-propanoyl-
valin)–chitosan (CHICO-val) and N-(c-propanoyl-aspartic acid)–chitosan (CHICO-asp). The main goal of this study was to
obtain data on the radiochemical and biological behaviour of these complexes and information regarding their therapeutic
potential when compared to 153Sm/166Ho-chitosan. Radiolabelling yield of 153Sm/166Ho-amino acid–chitosan complexes was
dependent on polymer concentration but less dependent on pH. Radiochemical stability was shown to be higher for amino
acid–chitosans than for chitosan, with 153Sm/166Ho-CHICO-val being stable up to 3 h, while 153Sm/166Ho-CHICO-asp is stable
up to 24 h. In the presence of ascorbic acid radiochemical stability of 153Sm/166Ho-CHICO-val and 153Sm/166Ho-CHICO was
improved, decreasing for 153Sm/166Ho-CHICO-asp. In vivo behaviour of 153Sm complexes was studied in mice. The
radioactive amino acid–chitosans can be directly injected into blood stream without significant retention on injection site,
being trapped by liver. Biodistribution studies suggest that the radioactive amino acid–chitosans, due to its water solubility
and stability may be considered potential candidates to be further explored for liver targeted nuclear therapy.
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Introduction
Internal radiation therapy (IRT) with unsealed b-emitting radio-
nuclides has emerged for the treatment of cancer as an
alternative to external radiotherapy. b-emitters have advantages
for the treatment of tumours owing to their physical character-
istics, in particular their short soft tissue penetration range,
delivering high radiation dose to tumour without adverse
radiation effects on the surrounding normal tissues.1 Among the
b-emitters, 166Ho (t1/2 26.8 h, bmax 1.85 MeV (51%), g 0.081 MeV
(7.5%) and 153Sm (t1/2 46.8 h, bmax 0.81 MeV (21%), g 0.103 MeV
(38%) appear to be good candidates for IRT.2
Chitosan, a polymer of 2-deoxy-2-amino-D-glucose obtained
by N-deacetylation of chitin has unique properties for a broad
variety of applications.3–5 Its chemical structure is characterized
by the degree of acetylation (DA), which also determines its
ability to chelate metal ions.3 Chemical modifications to
enhance chelating properties, selectivity and metal ion capacity
of chitosan have been proposed and various chitosan deriva-
tives have been designed to improve these features.6 Keeping
this in mind, N-(2-carboxyethyl)–chitosans have been prepared
and their metal complexation properties and potential applica-
tions have been studied.7–9
Owing to its capacity to complex b-emitter metal ions
through its amino groups, chitosan appears to be a promising
therapeutic alternative for local treatment of tumours.10 The
main features of these complexes are their solubility under
acidic conditions and the easy conversion to gel at the local of
administration (physiological pH), with the corresponding
retention of the radionuclide. Based on this principle,
153Sm/166Ho-chitosan complexes have been prepared with
relatively high radiochemical purity (490%) and their biological
behaviour has been considered promising for local therapy of
prostate and skin cancer,11–13 brain glioma,14 renal cysts15 and
rheumatoid arthritis.16–17 Following these results, 166Ho-chitosan
(DW-166HC) has been approved in Korea as a radiopharmaceu-
tical for the treatment of small hepatocellular carcinoma
(HCC).18,19 However, DW-166HC is sensitive to degradation
induced by radiation and its use immediately after synthesis is
highly required.
We have been working on the chemical modification of
chitosan amino groups in order to improve both the polymer
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properties, for potential biomedical applications.7–9 Recently,
we have prepared two novel amino acid–chitosan polymers,
N-(g-propanoyl-valin)–chitosan and N-(g-propanoyl-aspartic
acid)–chitosan, from low molecular weight chitosan and
Na-(3-bromopropanoyl)–valine or Na-(3-bromopropanoyl)–aspartic
acid, respectively.20 Structures of chitosan (CHICO, 1),
N-(g-propanoyl-valin)–chitosan (CHICO-val, 2a) and N-(g-propanoyl-
aspartic acid)–chitosan (CHICO-asp, 2b) are presented in Figure
1. In view of the interesting properties of our novel amino
acid–chitosan derivatives,21 we decided to explore the
coordination capability of these modified chitosan towards
153Sm/166Ho, two therapeutically relevant radionuclides. Herein,
we describe the synthesis of 153Sm/166Ho-N-(g-propanoyl-
valin)–chitosan and 153Sm/166Ho-N-(g-propanoyl-aspartic acid)–
chitosan as well as our data on their radiochemical and
biological behaviour as compared with the respective chitosan
analogous.
Results and discussion
Synthesis and stability of the radiolabelled complexes
Irradiation of 152Sm/Ho-nitrates yielded 140 MBq/mg (153Sm)
and 190 MBq/mg (166Ho) with high radionuclidic purity as
confirmed by the typical g-ray spectrum.22 The complexation
reaction conditions were optimized in order to obtain
153Sm/166Ho-complexes with high radiochemical purity. The
labelling yield of 153Sm/166Ho-CHICO–amino acid complexes
was not highly dependent on the pH, but depends on the
polymer concentration. Complexes were obtained with yields
higher than 98% at pH 3–7 with 1% (w/v) polymer solution,
while the complexation yield drastically decreases at lower
concentration (Table 1). In contrast, the labelling yield of
153Sm/166Ho-CHICO complexes was highly dependent on both
parameters, reaching only 98% at pHC3 and using a 1% CHICO
solution.11,16
The stability of the CHICO–amino acid complexes was
followed by ITLC, using the chromatographic systems indicated
in the experimental section. Both complexes have in vitro
radiochemical behaviour different than that of their CHICO
analogous. While the latter complex remains in the origin, in
accordance with its colloidal nature, the CHICO-asp and CHICO-
val complexes migrate with Rf values of approximately 0.4 and
0.6, respectively (Table 2). Nonetheless, in both cases the
presence of free radiolanthanide was never detected.
After formation, 153Sm/166Ho-CHICO-asp/CHICO-val com-
plexes showed relatively high radiochemical purity within a
sufficient time period for eventual clinical applications
(153Sm/166Ho-CHICO-val is stable up to 3 h and 153Sm/166Ho-
CHICO-asp is stable up to 24 h), while 153Sm/166Ho-CHICO
appeared to be more sensitive and degrading with storing.23 As
an example, we show in Figure 2 how fast 153Sm-CHICO
degrades leading to new radiochemical species with time. As
shown in Figure 2, 153Sm-CHICO leads to a new species with
RfE0.22, 30 min after formation, and with time new species are
formed progressively with higher Rf values. The amino acid
derivatives are stable for a longer period of time and the
decomposition corresponds to the formation of a new radio-
chemical species along with the original ones. The different
behaviour found for our complexes may be due to the presence
of one or two carboxylate groups in the chitosan backbone,
which may contribute for structural stabilization of the radio-
active complexes.
Considering that ascorbic acid (AA), an antioxidant radical
scavenger, is often used as a food additive or as a stabilizer in
radiopharmaceutical compositions,24,25 we have decided to
evaluate the effect of this compound on the radiochemical
stability of 153Sm/166Ho-chitosan derivatives and at the same
time on 153Sm/166Ho-chitosan. As can be seen in Figure 2,
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Table 1. Labelling yield vs polymer concentration at the
pH range 3–7





Table 2. Radiochemical behaviour of 153Sm/166Ho-amino acid–CHICO complexes
Rf
153Sm/166Ho-CHICO 153Sm/166Ho-CHICO-val 153Sm/166Ho-CHICO-asp 153Sm/166Ho(NO3)3
0 0.6 0.4 0.9–1.0
Figure 1. Molecular structures of chitosan (1), N-(g-propanoyl-valin)–chitosan (2a)
and N-(g-propanoyl-aspartic acid)–chitosan (2b).
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the radical scavenger has slightly improved the stability of
153Sm-CHICO, in agreement with the results previously de-
scribed by Zoldners et al.24 The stability of this compound seems
to be relatively dependent on the nature of the solution
components. In acetic acid solutions, for example, Zoldners et al.
described that chitosan degrades with the formation of more
water-soluble fragments along the time, as a result of oxidative
and hydrolytic splitting of the polymer chains. Moreover, it has
also been referred that 166Ho-chitosan is radiation sensitive,
heading for decreasing in the complex viscosity.23 The increase
stability of 153Sm-CHICO in the presence of AA may be due to
the effect of AA as a scavenger of possible radicalar species and/
or to the additional coordination capability of AA.23,24 Regarding
the 153Sm/166Ho-CHICO–amino acid complexes, the addition of
AA (2% AA solution) has significantly affected its radiochemical
behaviour. For compound 153Sm/166Ho-CHICO-val its stability
enhanced significantly up to 24 h. In contrast, the addition of AA
to 153Sm/166Ho-CHICO-asp resulted in a high degree of
degradation of the initial complexes, with formation of
several species. Based on the thermo-stability and structural
studies previously performed for CHICO and for CHICO-amino
acid polymers, by differential scanning calorimetry and
scanning electron microscopy, the CHICO-asp has a looser
macromolecular structure than its CHICO-val counterpart and a
highest thermo-sensitivity and water-holding capacity, which
implies that its supramolecular structure is weaker than that of
its counterpart (Figure 3).20,21 Thus, while CHICO-val has a
compact and continuous film-like structure, CHICO-asp has a
highly porous morphology, probably due to electrostatic
repulsions between its higher number of carboxylate groups.
The porous morphology of CHICO-asp may allow AA, a well-
known chelating agent,26,27 to efficiently penetrate into the
polymeric matrix and compete for metal complexation with
the polymer chelating groups. In CHICO-val the structure is
more compact and stable so another oxygen donor co-ligand
may lead to a mixed-ligand complex, which will be anchored on
the donor groups of the amino acids as well as on the AA,
leading to the stabilization of the radiometal by a synergic
effect.24,26
Biodistribution of the 153Sm-labelled complexes in mice
Preliminary biodistribution studies were only performed
for 153Sm-complexes. For comparison, 153Sm-CHICO was also
studied in the same animal model. As expected, the
153Sm-CHICO was almost completely retained at the site of
administration and no radioactivity excretion was found up to
24 h. On the contrary, the CHICO-amino acid complexes could
be injected directly into the blood stream by the tail vein. For
both complexes a high liver uptake was found, despite i.v.
injection and the excretion was very slow or negligible.
However, the two complexes have shown slightly different
biodistribution patterns (Figure 4). While 153Sm-CHICO-val was
associated to high hepatic radioactivity retention that enhanced
over time, the 153Sm-CHICO-asp was slowly cleared from the
liver into the intestine, which is a disadvantage if one wants to
treat liver cancer. Additionally, the uptake by the liver should be
speed up in order to reduce the radiation dose to the blood
cells. The significant retention of activity in the liver found for
153Sm-CHICO-val can probably be due to the in vivo formation of
radiochemical species of colloidal/polymeric nature.
Experimental
Chemicals: Enriched samarium oxide (Sm2O3, 98.4% as
152Sm)
was purchased from Campro Scientific and natural Ho2O3
(99.9%) from Strem. Chitosan (abbreviated CHICO)
(MW150 000; DA = 0.10) was supplied by Sigma-Aldrich.
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Figure 2. Radioactive distribution on the ITLC-SA strips of 153Sm-CHICO complex
obtained in the absence and presence of ascorbic acid over time.
Figure 3. SEM micrographs (100magnification) of CHICO (A), CHICO-val (B) and CHICO-asp (C).
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Instant thin layer chromatography (ITLC) strips were supplied
by Polygram, Macherey-Nagel. N-(g-propanoyl-valin)–chitosan
(abbreviated CHICO-val) and N-(g-propanoyl-aspartic acid)–chi-
tosan (abbreviated CHICO-asp) were synthesized and purified
according to methods previously reported.21 All materials were
reagent grade unless otherwise specified.
Synthesis of the peptide chitosan polymers: The synthesis of the
two novel CHICO-based polymers was reported in detail
elsewhere.21 Briefly, Na-(3-bromopropanoyl)-valine and Na-(3-
bromopropanoyl)-aspartic acid were prepared by reacting the
relevant L-amino acid tert-butyl esters with 3-bromopropanoic
acid in the presence of dicyclohexylcarbodiimide (DCCI) as
coupling reagent. After being isolated by column chromato-
graphy on silica, the tert-butyl esters were successfully identified
by 1H and 13C NMR. These esters were then cleaved by acidolysis
with neat TFA, with quantitative formation of the corresponding
free carboxylic acids Na-(3-bromopropanoyl)-valine and Na-(3-
bromopropanoyl)-aspartic acid, whose structures were also
confirmed by NMR. The carboxylic acids obtained as above
described were covalently attached to chitosan as follows:
chitosan was dissolved in water containing 4 M equivalents of
Na-(3-bromopropanoyl)-valine or Na-(3-bromopropanoyl)-aspar-
tic acid. The reactions were allowed to proceed at 601C under
magnetic stirring and with daily additions of NaHCO3 to keep pH
within the 6–8 range. The peptide–chitosans were purified by
dialysis against deionized water for 5–7 days, and then
freeze-dried.
Production of 153Sm and 166Ho: 153Sm and 166Ho were
produced by 152Sm(n,g)153Sm and 165Ho(n,g)166Ho reaction,
respectively, in the ITN Nuclear Research Portuguese Reactor
(1 MW). Irradiation was performed using nitrate targets (Sm/Ho,
10 mg) prepared from the correspondent isotopically enriched
152Sm2O3 or natural Ho2O3 under a thermal neutron flux
of 1.5 1013 n/cm2 s and epithermal neutron flux of
3.1 1011 n/cm2 s for 1–2 h. Following irradiation, the targets
were reconstituted in H2O to yield 1% (w/v)
153Sm/166Ho-nitrate
solution for complex preparation. The radionuclide purity was
assessed by g spectrometry with a Ge(Li)-detector (Canberra)
and activities were measured by a radioisotope calibrator (Aloka,
Curiemeter IGC-3, Tokyo, Japan).
Radiolabelling procedure: The preparation of 153Sm/166Ho-
complexes with a high labelling yield (498%) was optimized.
Typically, 40mL of 1% 153Sm(NO3)3 solution or 20 mL of 1%
166Ho(NO3)3 solution was added to 700 mL of CHICO or CHICO-
based polymer solution in 1% (v/v) acetic acid, followed by
thorough stirring for 20 min at room temperature. The
radiolabelling pH of the resulting solutions was 3.0 for
153Sm/166Ho-CHICO complex and 7.0 (by adding an appropriate
volume of 1 N NaOH solution) for 153Sm/166Ho-peptide-chitosan
based complexes. The labelling efficiency was accomplished by
ITLC, using ITLC-SA strips developed with MeOH:H2O:acetic acid
(50:50:0.5) as the mobile phase. In this system, the radiochemical
species migrate with the Rf presented in Table 2. Radioactive
distribution on the ITLC-SA strips was detected by using a
Berthold LB 505 detector coupled to a radiochromatogram
scanner. The stability of the 153Sm/166Ho-CHICO or 153Sm/166Ho-
CHICO-based complexes was assessed by measuring the radio-
chemical purity by ITLC over time, up to 24 h. The effect of the
radical scavenger AA (2% AA solution) on the stability of the
complexes was also studied.
In vivo studies: Biodistribution studies were carried out using
normal CD-1 mice from Charles River, Spain, according to
previously reported procedures.22 Animals were intravenously
injected, via the tail vein, or intraperitoneally injected with 100 ml
(3.7 MBq) of the radiolanthanide complexes. After 1 and 24 h
animals were killed by cervical dislocation, the main organs were
dissected and the radioactivity counted in a g counter (Berthold
LB 2111, Germany). Biodistribution results were expressed as
percent of injected dose per total organ (% I.D./organ).
Concluding remarks
Concerning the best strategy to deal with inoperable HCC, there
is a general lack of consensus. Classical approaches include
trans-arterial chemo-embolization (TACE) or IRT through admin-
istration of radionuclide–lipiodol complexes that have the
advantage of being highly retained by hepatic tumours.28–35
However, TACE is not suitable for advanced disease or patients
with an obstructed (thrombotic) portal vein, whereas radiola-
belled lipiodol (e.g. 131I-lipiodol) is associated with pain on
injection and occasional induction of severe pneumopa-
thies.30,31 Radioimunotherapy can be a way to circumvent
the above problems. But treatments with the monoclonal
131I-Hepama-1, though associated with low toxicity, usually
requires hepatic artery ligation, whereas polyclonal 131I rabbit
antiferritin IgG has been related to thromobocytopenia.31
Alternatively, radiolabelled glass or resin microspheres have
been explored as potentially safer IRT agents, but their clinical
efficacy has not been proved so far. Successful treatment of liver
tumours in an animal model was achieved with 166Ho-labelled
poly-(L-lactic acid) microspheres, which opens new possibilities
towards the use of microspheres built from biocompatible
materials.31 In this context, radiolabelled chitosan-based poly-
mers appear as a most attractive and cost-effective choice, as
chitosan is cheap, biodegradable, bioadhesive and biocompa-
tible, and has low toxicity and low immunogenicity. Indeed, the
approved 166Ho-chitosan complex (DW-166HC), was found to be
a highly effective and safe new radiopharmaceutical agent for
IRT against liver cancer.19 The CHICO-amino acid polymers,
described herein, were found to be suitable ligands for the
preparation of stable 153Sm/166Ho-complexes with high
labelling yields (498%) and high radiochemical purity over
the time. As compared with unmodified chitosan, the amino8
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Figure 4. Whole body excretion and biodistribution in the most relevant organs of
153Sm-CHICO complexes at 1 and 24 h after administration in mice.
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acid derivatives present several advantages for eventual clinical
applications: water solubility over a wide pH range and
quantitative formation of non-colloidal radiolanthanide
complexes. Despite their higher fluidity, the radiolabelled
CHICO-amino acid complexes have higher stability than their
CHICO counterparts and may be potentially interesting to be
explored for the treatment of HCC and liver metastasis, when
treating the whole liver makes it more suitable as compared
with resection or liver transplantation.36 In addition, in a
clustered metastasis or primary tumour, the cross-fire effect of
b energy particles might also be beneficial.36,37 Preliminary
biological results have shown that 153Sm-CHICO-amino acid
complexes present high liver uptake specially CHICO-val. This
targeting of the liver may also be exploited for liver-specific
targeting and with the appropriate radionuclide, for imaging.38
Whether the biodistribution profile of this radioactive amino
acid–chitosan could be improved in order to increase the blood
clearance and then minimize the radiation dose to non-target
organs the chance to administer it via i.v. injection may be a
significant advantage relatively to the compounds advocated for
the same purpose, which require local administration. The
improved radiochemical and biological characteristics of
153Sm/166Ho-CHICO–amino acid complexes highlight the
interest to further explore the chemical modification of chitosan
in order to introduce functional groups to modulate its
pharmacokinetics, coordination capability towards different
radionuclides and specificity to design specific radiotracers.39
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